The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 114 participants.

Also called NCT06427343

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 114 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06427343
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06427343. Randomized; single masking; primary purpose treatment. Start 2023-10-01 (actual); primary completion 2027-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency
Acronym
IRONDOSE
Condition
Heart Failure
Condition
Iron Deficiency
Intervention (Drug)
High-dose ferric derisomaltose
Intervention (Drug)
Low-dose ferric derisomaltose
Lead sponsor
China-Japan Friendship Hospital (class: other)

Record details

Record id
cardio:ct-nct06427343
Content hash
6a3ca59226bc19573a19b62f2e7de7838d864144d7994a507cf6fdf69a385803